MRKR Key Statistics, Chart & Performance
The current stock price of MRKR is 1.32 USD. In the past month the price increased by 49.85%. In the past year, price decreased by -61.63%.
MRKR Latest News, Press Relases and Analysis
MRKR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MRKR
Company Profile
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Company Info
MARKER THERAPEUTICS INC
2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311
Houston TEXAS 77027 US
CEO: Peter Hoang
Employees: 5
Phone: 17134006400
MARKER THERAPEUTICS INC / MRKR FAQ
What does MRKR do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
What is the current price of MRKR stock?
The current stock price of MRKR is 1.32 USD. The price decreased by -7.04% in the last trading session.
What is the dividend status of MARKER THERAPEUTICS INC?
MRKR does not pay a dividend.
What is the ChartMill technical and fundamental rating of MRKR stock?
MRKR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy MRKR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRKR.
What is the next earnings date for MRKR stock?
MARKER THERAPEUTICS INC (MRKR) will report earnings on 2026-03-30, after the market close.
What is the outstanding short interest for MARKER THERAPEUTICS INC?
The outstanding short interest for MARKER THERAPEUTICS INC (MRKR) is 1.85% of its float.
MRKR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MRKR. When comparing the yearly performance of all stocks, MRKR is a bad performer in the overall market: 72.46% of all stocks are doing better.
MRKR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRKR. MRKR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MRKR Financial Highlights
Over the last trailing twelve months MRKR reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -28.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.93% | ||
| ROE | -139.26% | ||
| Debt/Equity | 0 |
MRKR Forecast & Estimates
9 analysts have analysed MRKR and the average price target is 8.33 USD. This implies a price increase of 531.06% is expected in the next year compared to the current price of 1.32.
For the next year, analysts expect an EPS growth of 20.1% and a revenue growth -62.2% for MRKR